Stockscreener 앱 받기
2.65
5.36%
-0.15
시간 외 거래:
2.65
전일 마감가:
$2.80
열려 있는:
$2.8
하루 거래량:
417.25K
Relative Volume:
0.93
시가총액:
$250.65M
수익:
$72.76M
순이익/손실:
$35.34M
주가수익비율:
7.1757
EPS:
0.3693
순현금흐름:
$-62.91M
1주 성능:
-2.93%
1개월 성능:
-14.52%
6개월 성능:
+66.67%
1년 성능:
+82.76%
1일 변동 폭
$2.65
$2.80
1주일 범위
$2.535
$2.92
52주 변동 폭
$1.295
$3.235
Compugen Ltd Stock (CGEN) Company Profile
Compare CGEN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGEN
Compugen Ltd
|
2.65 | 264.84M | 72.76M | 35.34M | -62.91M | 0.3693 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Compugen Ltd Stock (CGEN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-07 | 개시 | Lake Street | Buy |
| 2026-01-07 | 개시 | H.C. Wainwright | Buy |
| 2025-01-13 | 개시 | Oppenheimer | Outperform |
| 2022-08-05 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-05-26 | 재개 | JMP Securities | Mkt Outperform |
| 2020-05-13 | 개시 | Stifel | Buy |
| 2020-05-07 | 개시 | SVB Leerink | Outperform |
| 2020-04-22 | 개시 | ROTH Capital | Buy |
| 2020-03-24 | 개시 | SunTrust | Buy |
| 2020-01-16 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-03-29 | 개시 | Oppenheimer | Outperform |
| 2016-02-01 | 재개 | Oppenheimer | Outperform |
| 2015-10-15 | 개시 | FBR Capital | Outperform |
| 2015-04-23 | 재개 | Jefferies | Buy |
| 2015-04-21 | 개시 | Oppenheimer | Outperform |
| 2014-02-07 | 개시 | MLV & Co | Buy |
| 2009-12-28 | 재확인 | Cantor Fitzgerald | Buy |
| 2009-07-29 | 개시 | Cantor Fitzgerald | Buy |
모두보기
Compugen Ltd 주식(CGEN)의 최신 뉴스
Compugen Ltd (CGEN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Compugen Q1 2026 earnings preview - MSN
Compugen surges after revenue tops forecasts despite quarterly loss miss (CGEN) - MSN
Leerink Partners Maintains Compugen(CGEN.US) With Buy Rating, Cuts Target Price to $5 - Moomoo
CGEN Maintains Outperform Rating -- Price Target Lowered to $5.0 - GuruFocus
H.C. Wainwright Maintains Compugen(CGEN.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Compugen Ltd. (NASDAQ:CGEN) Q1 2026 Earnings Call Transcript - Insider Monkey
Compugen (CGEN) Returns To Loss In Q1 2026 And Tests Bullish Profitability Narrative - simplywall.st
Lake Street Maintains Compugen(CGEN.US) With Buy Rating, Maintains Target Price $6 - Moomoo
Earnings Call Summary | Compugen(CGEN.US) Q1 2026 Earnings Conference - Moomoo
CGEN: AI-driven immuno-oncology pipeline advances, with strong partnerships and extended cash runway - TradingView
Compugen Ltd at Stifel Virtual Targeted Oncology Forum Transcript - GuruFocus
Compugen: 'Buy' As Early Gastric Cancer Data Reinforces Rilvegostomig Program (NASDAQ:CGEN) - Seeking Alpha
Compugen Q1 2026 Deep Dive: EPS Misses by 14.3%, Revenue Down 5% - AlphaStreet
Compugen : Corporate Presentation - marketscreener.com
Compugen (CGEN) Reports Q1 Revenue and Long-Term Financial Stabi - GuruFocus
Compugen Files $400 Million Mixed Shelf - Moomoo
Compugen Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Compugen Ltd. (NASDAQ: CGEN) files $400M shelf; $100M ATM with Leerink - Stock Titan
Compugen Q1 2026 Earnings Call Transcript - MarketBeat
Compugen Reports Q1 2026 Financial and Clinical Progress - grafa.com
Compugen Q1 Earnings Call Highlights - MarketBeat
Earnings call transcript: Compugen’s Q1 2026 revenue beats forecast, stock rises By Investing.com - Investing.com South Africa
CGEN: Strong cash position and advancing clinical programs set the stage for key 2026–2027 milestones - TradingView
Compugen Ltd reports results for the quarter ended March 31Earnings Summary - TradingView
Earnings call transcript: Compugen’s Q1 2026 revenue beats forecast, stock rises - Investing.com UK
CGEN: Solid cash position and pipeline progress set the stage for key clinical milestones in 2026 - TradingView
Compugen (CGEN) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Compugen Releases Q1 2026 Financial Results - AlphaStreet
Q1 2026 Compugen Ltd Earnings Call Transcript - GuruFocus
Compugen Ltd. (NASDAQ:CGEN) Q1 2026 Earnings Beat Sparks 12.73% Pre-Market Rally Amid Clinical Pipeline Progress - ChartMill
COMPUGEN ($CGEN) Releases Q1 2026 Earnings - Quiver Quantitative
Compugen earnings missed, revenue topped estimates - Investing.com India
Compugen 1Q Loss/Shr 8c >CGEN.TV - Moomoo
Compugen: Q1 Earnings Snapshot - Barchart
Compugen earnings missed, revenue topped estimates By Investing.com - Investing.com South Africa
Compugen Posts Q1 2026 Results, Cites Strong Cash Runway and Pipeline Advances - TipRanks
Press Release: Compugen Reports First Quarter 2026 Results - Moomoo
Compugen shares jump 18% on revenue beat despite earnings miss - Investing.com India
Compugen shares jump 18% on revenue beat despite earnings miss By Investing.com - Investing.com India
Earnings Scheduled For May 18, 2026 - Benzinga
Compugen 1Q Rev $2.18M >CGEN.TV - Moomoo
CGEN: Solid cash position and advancing clinical pipeline support operations into 2029 - TradingView
Compugen (CGEN) Q1 2026 results show cash runway to 2029 and $1B milestones - Stock Titan
Compugen cancer trials, AstraZeneca and Gilead deals, cash runway into 2029 - Stock Titan
Compugen Ltd (CGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):